• Moffitt Cancer Center continues to distinguish itself as a world leader in the development of novel immunotherapy treatments, capitalizing on the natural power of the body's immune system to defend itself against the growth and spread of cancerous cells. (moffitt.org)
  • It is a phase 2b randomized trial of autologous dendritic cell immunotherapy (CMN-001) plus standard treatment for advanced renal cell carcinoma after a nephrectomy ( MCC 21083 ). (moffitt.org)
  • This CMN-001 is an autologous, tumor antigen-loaded dendritic cell immunotherapy. (moffitt.org)
  • We currently test the safety and tolerability of experimental immunotherapy vaccines to treat brain tumors and Alzheimer's. (cedars-sinai.edu)
  • Novel understanding in the interaction between immune system and cancer cells of the patient holds great promise for immunotherapy development [ 4 - 6 ]. (hindawi.com)
  • It is noted that T cell has great potential for immunotherapy of hematological malignancies. (hindawi.com)
  • Since virtually all undifferentiated NPCs are associated with Epstein-Barr virus (EBV), this tumor is an attractive candidate for cellular immunotherapy targeted against tumor-associated viral antigens. (nih.gov)
  • Immunotherapy based on the adoptive transfer of ex vivo expanded and activated autologous tumor-reactive lymphocytes can mediate tumor regression in cancer patients. (unimedizin-mainz.de)
  • We successfully applied this strategy to the human TAAs p53, gp100 and MDM2-specific TCRs as promising antigens-driven immunotherapy for both melanoma and hematologic malignancies. (unimedizin-mainz.de)
  • This joint (Frankfurt/Mainz, Dresden, Essen, Heidelberg) translational immunotherapy project aims to combine NK cells as effector cells with universal epitope-specific CAR (UniCAR) with tunable activity. (unimedizin-mainz.de)
  • Immunotherapy is emerging as a new form to treat cancer by harnessing the activity of cytotoxic CD8 + T lymphocytes (CTLs) that specifically recognize tumor-associated antigens. (lifeboat.com)
  • Tumor stem cell-targeted immunotherapy for metastatic melanoma -a randomized phase 3 clinical trial. (ca.gov)
  • Therapeutic Candidate or Device Tumor stem cell-targeted immunotherapy. (ca.gov)
  • Dendritic cell immunotherapy for patients with metastatic renal cell carcinoma: University of Tokyo experience. (nwbio.com)
  • Large-scale immunomagnetic selection of CD14+ monocytes to generate dendritic cells for cancer immunotherapy: a phase I study. (nwbio.com)
  • Monocyte-derived dendritic cell (DC)-based anti-cancer immunotherapy represents a promising treatment modality in these neoplasias. (muni.cz)
  • Trial patients having undergone monocyte-interfering pharmacotherapy prior to monocyte harvest was associated with an impaired DC-based immunotherapy product outcome. (muni.cz)
  • ICT-107 is a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens. (genengnews.com)
  • This discovery demonstrates a complex immune response following administration of CLBS20 immunotherapy and is of critical importance for effective prediction of patient response to therapy. (bmj.com)
  • We now need to know how we can improve the current immunotherapy strategies so that not only a subset of patients respond, but even more patients can benefit from these therapies," Sharma said. (aacr.org)
  • Several types of ACT round out the immunotherapy arsenal, including chimeric antigen receptor (CAR) T-cell therapy, T-cell receptor (TCR) therapy, and tumor-infiltrating lymphocyte (TIL) therapy. (aacr.org)
  • Building off experience in hematopoietic stem cell transplant and exploiting advances in genetic engineering, genome editing, immunology, immunotherapy, stem cell biology, understanding disease mechanisms and cell therapy manufacturing, considerable progress has been made with hundreds of clinical trials underway. (bdbiosciences.com)
  • Because of this tumor-associated expression pattern, CTAs have been the focus of attention as potential targets in immunotherapy for cancer ( 2 ). (aacrjournals.org)
  • CONCLUSIONS: In HLA-A2-positive patients with advanced NSCLC and secondary resistance to immunotherapy, OSE2101 increased survival with better safety compared to CT. (bvsalud.org)
  • Nevertheless, ex vivo activation with cytokines can restore cytolytic activity of NK cells against GB, indicating that NK cells have potential for adoptive immunotherapy of GB if potent cytotoxicity can be maintained in vivo . (frontiersin.org)
  • Furthermore, similar to T cells, specific recognition and elimination of cancer cells by NK cells can be markedly enhanced through expression of chimeric antigen receptors (CARs), which provides an opportunity to generate NK-cell therapeutics of defined specificity for cancer immunotherapy. (frontiersin.org)
  • We then outline preclinical approaches that employ CAR-NK cells for GB immunotherapy, and give an overview on the ongoing clinical development of ErbB2 (HER2)-specific CAR-NK cells currently applied in a phase I clinical trial in glioblastoma patients. (frontiersin.org)
  • IMA101 is a personalized investigational immunotherapy being evaluated for the treatment of multiple cancers, including ovarian, gastric, esophageal, non-small cell lung cancers, and head and neck squamous cell carcinoma. (pharmacytimes.com)
  • Cancer immunotherapy with mRNA-transfected dendritic cells. (nova.edu)
  • Breast tumor infiltrating lymphocytes (TIL) are enriched in tumor-specific cytotoxic T lymphocytes (CTL), and may represent a superior source of CTL compare to peripheral blood lymphocytes (PBL), for adoptive T cell immunotherapy of breast cancer. (utmb.edu)
  • The combination of CD40L and OX40L on B-CLL cells may allow the generation of therapeutic immune responses to B-CLL, either by active immunization with modified tumor cells or by adoptive immunotherapy with tumor-reactive autologous T cells. (houstonmethodist.org)
  • Immunotherapy with monoclonal antibodies, such as ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. (survivornet.com)
  • Developed as the next generation of immunotherapy, it uses personal and precision vaccines as well as T cell therapies to direct T cells directly toward a patient's tumors. (patent-art.com)
  • The first chimeric antigen receptor- (CAR-) T cell immunotherapy, anti-CD19 CAR-T for B cell lymphoma, was approved by the USFDA in August 2017. (patent-art.com)
  • Rocapuldencel-T is an autologous dendritic cell immunotherapy for patients with metastatic renal cell carcinoma about which we have written previously. (shu.edu)
  • Involving the direct use of whole cells or cellular material in patients, cell therapy is an umbrella term for many subdivisions of biological research, encompassing fields such as stem cell therapy, gene therapy and immunotherapy. (ddw-online.com)
  • In particular, chimeric antigen receptor (CAR) - patient T cells genetically engineered to express antigen receptors targeting cancer cells - and organoid technologies (tiny, self-organized three-dimensional tissue cultures derived from stem cells) will continue to disrupt the cell and gene therapy and regenerative medicine fields, translating early successes with liquid cancers to solid tumors and beyond. (corning.com)
  • We further show that both hematologic cancers and solid tumors, including sarcomas and carcinomas, are amenable to myeloid-lineage reprogramming into TR-APCs. (lu.se)
  • MAINZ, Germany I September 9, 2022 I BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company") today presented positive follow-up data from its ongoing first-in-human Phase 1/2 trial evaluating the safety and efficacy of the Company's novel CAR-T cell therapy candidate, BNT211, in patients with relapsed or refractory advanced solid tumors. (pipelinereview.com)
  • The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of pembrolizumab/vibostolimab co-formulation (MK-7684A) with or without other anticancer therapies in participants with selected advanced solid tumors. (uci.edu)
  • This clinical trial is evaluating a drug called BT5528 alone and in combination with nivolumab in participants with advanced solid tumors historically known for expression of EphA2. (uci.edu)
  • Solid tumors, autoimmune diseases, graft versus host disease (GvHD), genetic diseases and neurodegenerative diseases are investigated using many types of autologous and allogeneic cells with rapidly evolving cell engineering and editing approaches. (bdbiosciences.com)
  • As a part of the approach, the antigens were validated as being present in solid tumors through the use of the XPRESIDENT target discovery platform, according to the release. (pharmacytimes.com)
  • The primary objective of the new study is to assess the safety and tolerability of the ACTolog therapy in patients with target-positive solid tumors, according to the release. (pharmacytimes.com)
  • and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers. (seekingalpha.com)
  • We're one of the few places looking at natural killer cells for solid tumors as well. (urotoday.review)
  • GEN-011 is an investigational, personalized neoantigen adoptive cell therapy (ACT) that is being developed by Genocea for the treatment of adult patients with advanced solid tumors. (uchicagomedicine.org)
  • Diagnosis of one of the following solid tumors: cutaneous melanoma, non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), urothelial carcinoma (UC), renal cell carcinoma (RCC), small cell lung cancer (SCLC), cutaneous squamous cell carcinoma (CSCC), anal squamous cell carcinoma (ASCC), merkel cell carcinoma (MCC). (uchicagomedicine.org)
  • Immunotherapies include checkpoint inhibitory antibodies, chimeric antigen receptor (CAR) T-cells, cancer vaccines, and oncolytic viruses. (moffitt.org)
  • In 1989, Zelig Eshhar and colleagues realized that the inability of T cells to recognize surface tumour antigens could be overcome by replacing domains of the T cell receptor (TCR) with antibody parts with specificity towards proteins on these cells. (nature.com)
  • In 2002, Michel Sadelain and colleagues optimized CAR design by integrating the intracellular domains of TCR and the key co-stimulatory receptor CD28 within a single molecule to help sustain T cell expansion, function and persistence. (nature.com)
  • Adoptive cell therapy (ACT) with chimeric antigen receptor T (CAR-T) cells can restore the activity of exhausted T cell through reprogramming and is widely used in the treatment of relapsed/refractory (r/r) hematological malignancies. (hindawi.com)
  • The most active T cell endogenous inhibitory pathway is the immunoglobulin superfamily such as CD28/cytotoxic T lymphocyte antigen-4 (CTLA-4): B7-1/B7-2 receptor/ligand grouping, which plays a central role in coordinating immune responses [ 7 , 8 ]. (hindawi.com)
  • Using HLA-A2.1 transgenic mice, we have demonstrated the feasibility of T-cell receptor (TCR) gene transfer into T cells to circumvent self-tolerance to the widely expressed human p53 and MDM2 TAAs. (unimedizin-mainz.de)
  • We therfore engineered NKT cells to express a chimeric antigen receptor (CAR) on their surface so that they directly kill NB tumor cells. (texaschildrens.org)
  • The candidate combines an autologous chimeric antigen receptor (CAR) T cell therapy targeting the oncofetal antigen Claudin-6 (CLDN6) with a CLDN6-encoding CAR-T cell amplifying RNA vaccine (CARVac). (pipelinereview.com)
  • The use of CD20 as suicide gene was investigated in CMV specific T cells and in T cells genetically modified with an antigen specific T-cell receptor. (haematologica.org)
  • CD20-transduced T cells with and without co-transferred T-cell receptor were efficiently eliminated by complement dependent cytotoxicity induced by therapeutic anti-CD20 antibody rituximab. (haematologica.org)
  • T-cell receptor (TCR) gene transfer is an attractive strategy for rapid in vitro generation of high numbers of antigen specific T cells. (haematologica.org)
  • Engineered chimeric antigen receptor (CAR) T cell therapies (CAR-T) are now commercially available to treat certain leukemias and lymphomas. (bdbiosciences.com)
  • CAR-T cells, which incorporate an antibody-derived extracellular receptor and T cell derived intracellular signaling domains, have shown convincing outcomes in certain types of leukemia and lymphoma, including commercial licensure of CD19 CAR-Ts for the treatment of relapsed/ refractory large B cell lymphoma and acute lymphoblastic leukemia. (bdbiosciences.com)
  • [ 2 ] Options for second-line therapy in patients with relapsed/refractory disease include chemotherapy-free regimens with biologic targeted agents such as covalent Bruton tyrosine kinase (BTK) inhibitors, lenalidomide,venetoclax, and chimeric antigen receptor (CAR) T-cell therapy. (medscape.com)
  • The company develops P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). (seekingalpha.com)
  • This is a Phase 1 study of central nervous system (CNS) locoregional adoptive therapy with autologous CD4 and CD8 T cells lentivirally transduced to express a HER2-specific chimeric antigen receptor (CAR) and EGFRt, delivered by an indwelling catheter in the tumor resection cavity or ventricular system in children and young adults with recurrent or refractory HER2-positive CNS tumors. (fredhutch.org)
  • The isolated T cell clones or T cell receptor (TCR-) engineered T lymphocytes establish the epitope patterns of neoantigens recognized by T cells. (patent-art.com)
  • Their modifications include adding a chimeric antigen receptor specific for B7-H3 and partnering with Fate Therapeutics to make four genetic modifications to these cells. (urotoday.review)
  • What we've done is we've been able to engineer natural killer cells and then we've added a chimeric antigen receptor specific for B7-H3. (urotoday.review)
  • T-cell therapies based on chimeric antigen receptor (CAR) T-cells are widely employed for this purpose, as they have the capacity to proliferate within the patient after infusion and offer sustained functional immunity. (ddw-online.com)
  • In these pioneering studies by Steven Rosenberg, tumour-infiltrating lymphocytes (TILs) were isolated from patients with melanoma, then activated and expanded before reinfusion into the patients. (nature.com)
  • The vaccine induces cytotoxic T lymphocytes to disrupt cancer stem cell antigens. (cedars-sinai.edu)
  • Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. (nwbio.com)
  • 3 Autologous lymphocytes genetically modified with the TCR for MART-1/Melan-A have been adoptively transferred to patients with advanced melanoma. (haematologica.org)
  • Although human CD20 has previously been described as functional selection marker and suicide gene after retroviral transfer to T lymphocytes, 9 , 10 the specificities of these T cells were unknown, and therefore a potential effect of CD20 on antigen-specific T-cell functions could not be investigated. (haematologica.org)
  • Adoptive cell therapy using tumor-infiltrating lymphocytes (TILs) has shown activity in melanoma, but has not been previously evaluated in metastatic non-small cell lung cancer. (nature.com)
  • Coupled with well-established in vitro culture and expansion protocols for T lymphocytes, CAR enabled the antigen-directed cytotoxicity of T cells to be harnessed, expanding the scope of cell therapy. (scienceboard.net)
  • In contrast to other cancers such as adenocarcinomas of the lung or melanoma, primary brain tumors like GB and low grade gliomas (LGG) are known as rather immunologically "cold" tumors, typically with low numbers of tumor-infiltrating lymphocytes (TILs) ( 4 ), and the mere amount of TILs is not associated with patient survival ( 5 ). (frontiersin.org)
  • The clinical trial is the first to use products consisting of autologous cytotoxic T lymphocytes that target tumor antigens using Immatics' target warehouse, according to a press release. (pharmacytimes.com)
  • I. Evaluate the safety and efficacy of adoptively transferred cytotoxic T-lymphocytes (CTL) targeting melanoma tumors combined with anti-CTLA4. (survivornet.com)
  • Neoantigens can be presented by the major histocompatibility complex (MHC, also known as human leukocyte antigen (HLA) in humans) on the cell surface and recognized by the T lymphocytes. (patent-art.com)
  • However, some patients present without lymphadenopathy but with abnormal lymphocytes in circulation. (msdmanuals.com)
  • In vivo TR-APC induction elicits clonal expansion of cancer-specific T cells, establishes cancer-specific immune memory, and ultimately promotes leukemia eradication. (lu.se)
  • Vaccination-induced Trm cells were largely resistant to in vivo intravascular staining and antibody-dependent depletion. (lifeboat.com)
  • Autoimmune side effects, however, remain a risk, emphasizing the relevance of a suicide mechanism allowing in vivo elimination of infused T cells. (haematologica.org)
  • Adverse side effects, however, may occur and lead to severe autoimmunity or graft-versus-host disease (GvHD), emphasizing the relevance of a suicide mechanism that allows efficient in vivo elimination of infused T cells. (haematologica.org)
  • Transfer of HSV-tk to DLI preserves the beneficial anti-tumor effect and allows in vivo elimination of donor T cells if severe GvHD occurs. (haematologica.org)
  • Autologous TILs were expanded ex vivo from minced tumors cultured with interleukin-2. (nature.com)
  • T cells are modified ex vivo by transduction with viral vectors containing CAR or other modifications of interest. (bdbiosciences.com)
  • July 20, 2021 -- Cellular reprogramming of ex vivo cells may offer improvements on first-generation adoptive cell therapies, which have experienced limited clinical success due to complex manufacturing, potential patient rejection, and availability of clinical cell types. (scienceboard.net)
  • First-generation ex vivo cell therapies, such as autologous anti-CD19 CAR T cells, demonstrated the clinical value and curative potential of enhancing the therapeutic qualities of immune and other patient-derived cell types. (scienceboard.net)
  • Here, we discuss effects of the GB tumor microenvironment on NK-cell functionality, summarize early treatment attempts with ex vivo activated NK cells, and describe relevant CAR target antigens validated with CAR-T cells. (frontiersin.org)
  • Secondary objectives include, feasibility, persistence of T-cells in vivo , and assessment of anti-cancer activity, and biomarkers. (pharmacytimes.com)
  • Loading DCs ex vivo with tumor antigens can stimulate potent antitumor immunity in tumor-bearing mice. (nova.edu)
  • I. Evaluate the influence of anti-CTLA4 on the duration of in vivo persistence and anti-tumor efficacy achieved following adoptive transfer of antigen-specific CTL. (survivornet.com)
  • ATLAS-identified neoantigens will be used to stimulate and select autologous T cells collected by apheresis to generate an adoptive cell product ex vivo. (uchicagomedicine.org)
  • Emerging data suggest that the combination of DC-based vaccination with other cancer therapies may fully unleash the potential of DC-based cancer vaccines and improve patient survival. (moffitt.org)
  • Adoptive cell therapies (ACT) leverage this cytotoxic capacity of T cells to eradicate tumours. (nature.com)
  • When effectively leveraged, they can reduce the cost and risks associated with novel therapies by enabling precisely targeted treatments for individual patients. (corning.com)
  • Key to optimizing patient outcomes is an understanding of the evolution and current role of these therapies in the HCC landscape. (bvsalud.org)
  • With advances in locoregional therapy for unresectable HCC during the last 2 decades and the recent expansion of transplant criteria for HCC, as well as ongoing organ shortages, patients are spending more time on the waitlist, which has resulted in an increased usage of locoregional therapies. (bvsalud.org)
  • We analyzed clinical data to evaluate the frequency of intracranial progression in advanced NSCLC patients treated with PD-1 blockade therapies compared with those treated without PD-1 blockade therapies, and found that the frequency of intracranial progression in advanced NSCLC patients treated with PD-1 blockade therapies was significantly lower than that in patients treated with cytotoxic chemotherapies. (bvsalud.org)
  • Therapeutic Candidate or Device Cryopreserved autologous TRAC locus 1XX BCMA-CAR T cells Indication Relapsed and Refractory Multiple Myeloma Therapeutic Mechanism Engineered T cells target and kill BCMA+ Myeloma cells Unmet Medical Need No durable treatments are available for RRMM and only ~30% of patients can access current BCMA CAR therapies. (ca.gov)
  • Therapeutic Candidate or Device Allogeneic iPSC derived dopamine progenitors delivered to the brain of Parkinson's disease patients Indication Idiopathic Parkinson's disease Therapeutic Mechanism The cellular product reconstitutes dopaminergic neuron circuits lost owing to the disease Unmet Medical Need There are currently disease modifying therapies. (ca.gov)
  • It can only be achieved if we manage to effectively deliver such therapies to our patients. (b3cnewswire.com)
  • Minaris Regenerative Medicine is a global contract development and manufacturing organization (CDMO) for cell and gene therapies. (b3cnewswire.com)
  • Our facilities in the US, Europe, and Asia allow us to supply patients worldwide with life-changing therapies. (b3cnewswire.com)
  • Although only a handful of cell and gene therapies are on the market, FDA officials predicted in 2019 that the agency will receive more than 200 investigational new drug applications per year for cell and gene therapies, and that by 2025, it expects to have accelerated to 10 to 20 cell and gene therapy approvals per year. (ajmc.com)
  • In total, 3 CAR T-cell therapies are now on the market, all targeting the CD19 antigen. (ajmc.com)
  • PCT's competencies in autologous cell therapies, cell manufacturing, cell processing, and delivery make it ideally suited as a manufacturer for ImmunoCellular Therapeutics as we look forward to completing this Phase II trial and seek to secure a strategic partner in connection with a future potential Phase III trial for ICT-107 and its commercialization," states Manish Singh, Ph.D., ImmunoCellular Therapeutics president and CEO. (genengnews.com)
  • While many successful immunotherapeutic regimens have relied on checkpoint inhibition, other immunotherapeutic approaches, such as adoptive cellular therapies (ACT), the use of bispecific antibodies, and targeting components of the tumor microenvironment, are showing promise in a variety of cancer types. (aacr.org)
  • Investigational cell therapies are addressing a wide range of hematological malignancies. (bdbiosciences.com)
  • The clinical success of anti-CD19 CAR T-cell therapies has not only provided efficacious treatment alternatives for cancer patients but also aided the developmental and regulatory precedent for the translation of cell-based therapies for other disease areas. (scienceboard.net)
  • Developing next-generation cell therapies centers around the enhancement of efficacy, safety, and accessibility. (scienceboard.net)
  • Prior to the invention of CAR, cell therapies were largely limited to allogeneic hematological transfusion and transplantation. (scienceboard.net)
  • Biological therapies, such as aldesleukin, use substances made from living organisms that may stimulate the immune system in different ways and stop tumor cells from growing. (survivornet.com)
  • There are other (or newer) ICIs (such as anti-PD1 and anti-PD-L1 antibodies), considered to be effective therapies in subsets of patients with a variety of tumor types such as metastatic melanoma, non-small cell lung cancer (NSCLC), prostate cancer, renal cell carcinoma, and so on. (patent-art.com)
  • While CAR-T therapies have shown significant promise in acute lymphoid leukaemia, treating solid cancers with CAR-T cells remains a challenge due to the lack of suitable tumor-associated antigens and low overall objective response rates. (patent-art.com)
  • Alicia Morgans interviews Nick Zorko, who shares his excitement about his team's work on natural killer (NK) cell therapies, specifically focusing on engineered NK cells to target the tumor marker B7-H3. (urotoday.review)
  • Dr. Zorko believes that NK cell therapies will be safer, more accessible, and possibly suitable for outpatient settings, which is particularly beneficial for prostate cancer patients who are often older and may have multiple comorbidities. (urotoday.review)
  • So the University of Minnesota is very focused on natural killer cell therapies. (urotoday.review)
  • As such, preserving the integrity of sensitive samples is a daily challenge for cell culture laboratories in their search for innovative new therapies. (ddw-online.com)
  • For research purposes, autologous cell therapies are often favoured because they do not require immunological matching and are personalised to the patient. (ddw-online.com)
  • One area in which autologous therapies have shown particular potential is in the treatment of cancer. (ddw-online.com)
  • Immuno-oncology therapies typically use genetically modified T-cells to combat and kill cancerous tissue by identifying the cancer cells as a foreign body in need of attack. (ddw-online.com)
  • These innovative therapies rely on the use of techniques and technologies that minimise the risk of contamination and achieve the strictly-controlled, secure environment necessary for growing healthy, viable cells. (ddw-online.com)
  • While cell therapies show great promise in bringing innovative and much needed treatments to patients, there are a number of key issues currently limiting their broader adoption. (ddw-online.com)
  • Safety concerns over the administration of live cells to patients, uncertainties over the way in which these therapies should be regulated, unknown downstream effects and the need for sufficient investment to fully commercialise research are all challenges that must be overcome in order to accelerate further development of cell therapies. (ddw-online.com)
  • The regulations surrounding cell therapies must therefore be sufficiently broad to cover this wide range of therapeutic processes, while still safeguarding product safety and quality. (ddw-online.com)
  • From a manufacturing point of view, autologous cell therapies can be more challenging to produce than allogeneic cell therapies, as each dose is a single batch and is derived from a different source. (ddw-online.com)
  • Some localized melanomas may result from azathioprine, which acts synergistically with ultraviolet radiation, while T-cell depleting induction therapies may promote late stage tumors. (cdc.gov)
  • Therapeutic Candidate or Device Tissue implant engineered using expanded, allogeneic chondroprogenitor cells Indication Defects of the temporomandibular joint disc complex Therapeutic Mechanism Though the mechanism has not been established, Hyaleon®️ may initially act as a load bearing structure that fills defects of the temporomandibular joint (TMJ) disc complex. (ca.gov)
  • Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. (nwbio.com)
  • Herpes simplex virus thymidine kinase (HSV-tk) is a well-established suicide gene that has been successfully used to control GvHD following donor lymphocyte infusions (DLI) after allogeneic stem cell transplantation. (haematologica.org)
  • 4 In addition, TCRs for minor histocompatibility antigens, including HA-1 and HA-2, have been transferred to donor-derived virus-specific T cells to treat patients with hematologic malignancies after allogeneic stem cell transplantation. (haematologica.org)
  • T-cell clones were stimulated every 10-14 days with irradiated allogeneic PBMC and phyto-hemagglutinin in IMDM with 5% human serum (HS), 5% FBS and 100 IU/mL IL-2 as previously described. (haematologica.org)
  • Techniques such as cellular reprogramming will allow the exploration of scalable allogeneic cell sources and the optimizable generation of cells for therapeutic development. (scienceboard.net)
  • As a result, developmental trends have shifted toward an allogeneic approach, seeking to replace autologous cell sources with consistent and scalable alternatives, such as iPSCs. (scienceboard.net)
  • The benefits of an allogeneic "off-the-shelf" cell therapy approach are clear: batch-producing cells derived from an unrelated donor or universal cell source that can be used to treat many patients. (scienceboard.net)
  • The culture of CD40L/OX40L-expressing B-CLL cells with autologous T cells generated CD4 + /CD8 + cytotoxic T-cell lines, which secreted interferon-γ (IFN-γ) and granzyme-B/perforin in response to autologous, but not to allogeneic, B-CLL cells or to autologous T-cell blasts. (houstonmethodist.org)
  • The cells used in transplantation can either be derived from an individual patient (autologous cell therapy) or from another donor (allogeneic cell therapy). (ddw-online.com)
  • Allogeneic methods are more akin to the pharmaceutical model of drug manufacturing as products can be produced on a larger scale and can be prepared for 'off the shelf' distribution, provided the recipients have an immunological profile matching the cells or cell products. (ddw-online.com)
  • Cell therapy manufacturing processes can range from the simple expansion of autologous cells that will be administered back to patients, to the complex genetic manipulation of allogeneic cells that could be stored and banked for the treatment of multiple patients. (ddw-online.com)
  • This group etic stem cell transplant (HSCT) (8 allogeneic) and in 15 of patients has also been disproportionately represented patients with malignancy treated at 6 Australian tertiary cen- among those with severe infections from infl uenza A pan- ters during winter 2009. (cdc.gov)
  • The finding that CAR T cells had activity in patients advanced the field of ACT, which saw dramatic progress in the following years and remarkable results in B-cell malignancies, including paediatric and adult acute lymphoblastic leukaemia (ALL), aggressive B cell lymphomas, chronic lymphocytic leukaemia and multiple myeloma treated with CD19 CAR T cells. (nature.com)
  • In this review, we aim to summarize the composition of CAR-T cell and its application in the treatment of acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), Hodgkin's lymphoma (HL), multiple myeloma (MM), and acute myeloid leukemia (AML). (hindawi.com)
  • The technique has also shown preliminarily promising outcomes in B cell acute lymphoblastic leukemia (B-ALL), B cell non-Hodgkin's lymphoma (B-NHL), chronic lymphocytic leukemia (CLL), Hodgkin's lymphoma and multiple myeloma in clinical trials targeting CD19, CD20, CD22, CD30 and B-cell maturation antigen (BCMA), with many more under investigation. (bdbiosciences.com)
  • We initiated a study to evaluate the antitumor efficacy of T cells engineered with an affinity-enhanced TCR specific for the NY-ESO-1 and LAGE-1 cancer testis antigens (NY-ESO c259 -T) in multiple myeloma (MM) patients with antigen-positive tumors in the setting of an autologous stem cell transplant (NCT01352286). (biomedcentral.com)
  • Validation of clinical-grade whole genome sequencing reproduces cytogenetic analysis and identifies mutational landscape in newly-diagnosed multiple myeloma patients: A pilot study from the 100,000 Genomes Project. (cdc.gov)
  • Elevated programmed cell death-1 protein/ligand (PD-1/PD-L1) and variants are associated with susceptibility to multiple myeloma: a case-control study in the Chinese cohort. (cdc.gov)
  • Whole-Exome sequencing analysis identified TMSB10/TRABD2A locus to be associated with carfilzomib-related cardiotoxicity among patients with multiple myeloma. (cdc.gov)
  • Prognostic Impact of IL17 A Gene Polymorphismson Egyptian Patients with Multiple Myeloma. (cdc.gov)
  • Smoldering) multiple myeloma: mismatch between tumor load estimated from bone marrow biopsy at iliac crest and tumor load shown by MRI. (cdc.gov)
  • Therapeutic cancer vaccination seeks to elicit activation of tumor-reactive T cells capable of recognizing tumor-associated antigens (TAAs) and eradicating malignant cells. (lu.se)
  • In 2017, two studies - the phase II ZUMA-1 trial led by Sattva Neelapu and a case-series study led by Carl June - validated the efficacy of CD19 CAR T cells in patients with refractory B-cell leukaemia and lymphoma. (nature.com)
  • Phase I evaluation of thrice-daily intravenous bolus interleukin-4 in patients with refractory malignancy. (nwbio.com)
  • Kite Pharma, a subsidiary of Gilead, received an accelerated approval in July 2020 for brexucabtagene autoleucel (Tecartus) for adults with relapsed or refractory mantle cell lymphoma. (ajmc.com)
  • This study is for patients diagnosed with relapsed or refractory high-risk neuroblastoma. (texaschildrens.org)
  • Immatics expects to enroll up to 20 patients with relapsed and/or refractory solid cancers that have no current treatment options, according to the release. (pharmacytimes.com)
  • A child or young adult with a refractory or recurrent CNS tumor will have their tumor tested for HER2 expression by immunohistochemistry (IHC) at their home institution or at Seattle Children's Hospital. (fredhutch.org)
  • They combined the variable region of an antibody with the constant regions of the TCR chains, thus producing chimeric antigen receptors (CARs) that provided T cells with antibody-type specificity. (nature.com)
  • However, this complex alone is insufficient to trigger productive T cell responses, which require the concomitant engagement of co-stimulatory receptors. (nature.com)
  • Chimeric antigen receptors (CAR)-engineered T cells have demonstrated remarkable efficacy in patients with B-cell malignancies. (unimedizin-mainz.de)
  • Transfusion of autologous tumor-specific CTLs 1-4 and blockade of T cell inhibitory receptors 5-7 have demonstrated to elicit durable clinical benefit in a significant proportion of patients with melanoma, leukemia, lymphoma and other cancers, who failed to respond to conventional treatments. (lifeboat.com)
  • The key to curing every single cancer, which is our goal, is to have receptors that can recognize the tumor but don't recognize the normal cells. (ajmc.com)
  • Receptors recognizing and then attacking normal cells is what can cause toxicity. (ajmc.com)
  • Related T cell approaches such as engineered T cell receptors also show promise. (bdbiosciences.com)
  • NK cells contribute to cancer immune surveillance not only by their direct natural cytotoxicity which is triggered rapidly upon stimulation through germline-encoded cell surface receptors, but also by modulating T-cell mediated antitumor immune responses through maintaining the quality of dendritic cells and enhancing the presentation of tumor antigens. (frontiersin.org)
  • The UniCAR is only activated upon cross-linking through a soluble tumor-targeting module carrying the UniCAR binding epitope, thereby achieving highest tumor specificity. (unimedizin-mainz.de)
  • T cells and TCR will be obtained from blood and tumor tissue and tested for neoantigen specificity and tumor reactivity. (unimedizin-mainz.de)
  • We have identified TCR sequences in CD8T cell clones which downstream analysis of antigen specificity will be assessed by the Denver team. (dtic.mil)
  • Additional efforts are needed to improve the response rates and tumor antigen specificity of ICI, and address the incidence of immune-related adverse events. (patent-art.com)
  • With their ability to serve as valuable model systems for studying the tumor microenvironment, organoids are accelerating discovery efforts in cancer biology and enabling rapid screening of potential new therapeutics. (corning.com)
  • The fourth generation of CAR-T design attempts to deliver cytokines to modulate the tumor microenvironment either by activating host effector T cells or hampering host suppressors and reinforcing memory T cells. (bdbiosciences.com)
  • While GB tumors are frequently infiltrated by natural killer (NK) cells, these are actively suppressed by the GB cells and the GB tumor microenvironment. (frontiersin.org)
  • Nevertheless, the composition of the immunologic tumor microenvironment undergoes changes upon radiotherapy, chemotherapy, or even after anti-angiogenic therapy ( 6 ). (frontiersin.org)
  • Chemokine signaling regulates both malignant cells and stromal cells of the tumor microenvironment (TME), constituting a potential therapeutic target against brain cancers. (researchportal.be)
  • The theoretical basis for marrow failure includes primary defects in or damage to the stem cell or the marrow microenvironment. (medscape.com)
  • The microenvironment of the oral cavity changes with the age of the patient, the eruption or loss of teeth, and the appearance of disease states (eg, caries, periodontal disease). (medscape.com)
  • Patients with human leukocyte antigen (HLA)-A2-positive advanced NSCLC without actionable alterations, failing sequential or concurrent CT and ICB were randomized (2 : 1) to OSE2101 or SoC (docetaxel or pemetrexed). (bvsalud.org)
  • Traditionally, the treatment of hematological malignancies is administrated by chemotherapy, radiotherapy, and stem cell transplantation. (hindawi.com)
  • Treatment selection takes into account patient age, fitness, and whether autologous stem cell transplantation (ASCT) is planned. (medscape.com)
  • With few exceptions, stem cell transplantation is usually reserved for patients with aggressive lymphomas after incomplete remission or relapse. (msdmanuals.com)
  • Using syngeneic murine leukemia models, we demonstrate that TR-APCs acquire both myeloid phenotype and function, process and present endogenous TAAs, and potently stimulate TAA-specific CD4+ and CD8+ T cells. (lu.se)
  • However, high-avidity T cells specific for tumor-associated antigens (TAAs) are usually absent in patients because of self-tolerance. (unimedizin-mainz.de)
  • CAR-T cells target the tumor-associated antigens (TAAs), such as CD19 in B cell malignancies and ERBB2 in breast cancers, which are also expressed in normal cells. (patent-art.com)
  • In 2010, James Kochenderfer and colleagues achieved a breakthrough with a CAR T cell therapy, reporting tumour regression in a patient with advanced follicular lymphoma, who received two infusions of autologous T cells genetically engineered to express a CAR specifically recognizing the antigen CD19 expressed on B cells. (nature.com)
  • Later that year, CD19 CAR T cells received US FDA approval for the treatment of children with ALL and adults with aggressive lymphomas. (nature.com)
  • Of note, CD19, CD20, CD30, CD33, CD123, and CD269 as ideal targets have shown extraordinary potential for CAR-T cell therapy and other targets such as CD23 and SLAMF7 have brought promising future for clinical trials. (hindawi.com)
  • Interestingly, vaccination-induced Trm cells strongly suppress the growth of melanoma, independently of circulating CD8 T cells, and were able to infiltrate melanoma tumors. (lifeboat.com)
  • In order to determine whether isolated CSC populations contained antigenic cancer-related mutations, exomic sequencing was performed on tumor cell lines from 5 distinct melanoma tumors using Illumina's sequencing technology. (bmj.com)
  • Entering clinical development with our first adoptive cell therapy program is a significant step for Immatics, and highlights the ability of the XPRESIDENT platform to identify novel and true tumor antigens directly from a patient's tumor," said Harpreet Singh, PhD, chief scientific officer and CEO at Immatics US. (pharmacytimes.com)
  • There are increasing neoantigen-based cancer vaccines designed to target the unique immunogenic mutations in each patient's tumor. (patent-art.com)
  • A proprietary tool developed by Genocea called ATLAS™ (Antigen Lead Acquisition System) will be used to identify true immunogenic neoantigens from each patient's tumor that are recognized by their own CD4 and/or CD8 T cells. (uchicagomedicine.org)
  • Such strategies could produce organisms that perform multistep immune functions such as presenting antigen to and co-stimulating helper T cells in a specific manner, or providing integrated signals to B cells to induce affinity maturation and isotype switching during antibody production. (wikipedia.org)
  • Technologies that can control cell fate include strategies to induce pluripotent stem cell formation and using small molecules to induce stem cells to differentiate into specific cell types. (wikipedia.org)
  • To induce an efficient anti-tumor response against the patients' own tumor cells, the encapsulated GM-CSF secreting cells are implanted subcutaneously at the site of tumor-cell vaccination. (b3cnewswire.com)
  • Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. (nwbio.com)
  • The therapy (CLBS20, also known as NBS20) uses purified autologous CSCs, derived from a patient's own tumor and grown as a tumor cell line, as the antigen source of tumor-associated antigens to induce or enhance an anti-tumoral immune response. (bmj.com)
  • Donor T cells may also induce GvHD due to recognition of allo-antigens on non-malignant tissues of the patient. (haematologica.org)
  • It may also invade and proliferate within heart and coronary artery endothelial cells, and, along with Streptococcus sanguis, it may also induce platelet aggregation associated with thrombus formation. (medscape.com)
  • Therapeutic vaccines treat and immunize patients already infected with a given disease. (wikipedia.org)
  • Advances in chemical biology include synthetic molecules that modulate B cell activation, structurally complex carbohydrate tumor antigen and adjuvants synthesis, immunogenic chemotherapeutic agents and chemically homogeneous, synthetic vaccines. (wikipedia.org)
  • The Breast Oncology Department , for example, has developed innovative clinical trials for vaccines that offer new ways to treat various types and stages of breast cancer and improve patient outcomes. (moffitt.org)
  • Dendritic cell vaccines can potentially be used to treat different cancer types. (moffitt.org)
  • Here, we demonstrated that intradermal administration of clinically relevant vaccines efficiently induces Trm cells specific for tumor-specific and self-antigens that accumulate in vaccinated and non-vaccinated skin. (lifeboat.com)
  • Here we demonstrated that a single intradermal administration of gene- or protein-based vaccines efficiently induces specific Trm cell responses against models of tumor-specific and self-antigens, which accumulated in vaccinated and distant non-vaccinated skin. (lifeboat.com)
  • Maturation and trafficking of monocyte-derived dendritic cells in monkeys: implications for dendritic cell-based vaccines. (nwbio.com)
  • We conclude that the DC-manufacturing yield and the immunostimulatory quality of anti-cancer DC-based vaccines generated from the monocytes of patients were not influenced by the monocyte isolation modality but were detrimentally affected by the specific combination of anti-cancer agents used prior to monocyte harvest. (muni.cz)
  • Cancer-testis antigens (CTA), a family of tumor-associated antigens, have both potent immunogenicity and restricted expression patterns in normal adult tissues, highly desirable characteristics for targets of anticancer vaccines. (aacrjournals.org)
  • Investigators hypothesized that adjunctive therapy with patient-specific vaccines could help to improve these outcomes in patients by boosting immune response. (oncnursingnews.com)
  • The key objectives of the trial include confirmation of the feasibility of producing patient-specific vaccines, the safety of administering these vaccines, survival from the date of enrollment, PFS from date of enrollment, and survival from the date of diagnostic surgical resection. (oncnursingnews.com)
  • Neoantigen cancer vaccines are capable of eliciting strong T cell responses to neoepitopes in patients with melanoma. (patent-art.com)
  • Neoantigen vaccines and immune checkpoint inhibition act as complementary treatments that might often be used together, especially for patients with large tumors or metastatic disease, and can lead to an increased tumor-specific immune response. (patent-art.com)
  • Rosenberg spoke of the benefit of TIL therapy in patients with metastatic melanoma. (aacr.org)
  • Giving autologous CD8+ antigen-specific T cells with cyclophosphamide, aldesleukin, and ipilimumab may be an effective treatment for patients with metastatic melanoma. (survivornet.com)
  • In 2011, FDA first approved an immune checkpoint inhibitor (ICI), ipilimumab, a monoclonal antibody targeting CTLA-4, which extended the overall survival rate of patients with metastatic melanoma. (patent-art.com)
  • In addition, once it has been demonstrated that these technologies have broad usability, they will serve as a foundation that can help reduce risks - both to patients and in terms of costs and timelines - of future clinical trials. (corning.com)
  • Vaccination strategies eliciting CTL responses specific for tumor-specific and self-antigens have shown promising results in recent clinical trials. (lifeboat.com)
  • This classification is fundamental to the type of marketing authorization (MA), and therefore to the controls to be performed, from preclinical stages through clinical trials to pharmacovigilance, to meet the safety requirements for patients. (frontiersin.org)
  • Specifically, he is interested in the utilization of compounds with novel mechanisms of action in clinical trials for the treatment of these tumors. (mdanderson.org)
  • PCT served as primary manufacturer for Dendreon during seven years of clinical trials for its prostate cancer cell-based treatment, Provenge. (genengnews.com)
  • In this case, CARs include a part specific for the GD2 molecule, which is present at high levels in NB tumors and has already led to promising results in clinical trials of GD2-targeted T cells in NB patients. (texaschildrens.org)
  • T cell-targeted immunomodulators such as monoclonal antibodies against PD-1 or CTLA4 may be used in combination with CAR-T cells in clinical trials. (bdbiosciences.com)
  • Several CTAs, including NY-ESO-1, MAGE-A3, and MAGE-A4, have been or are being studied as target antigens in vaccine clinical trials for various types of tumors, including non-small-cell lung cancer, ovarian cancer, gastrointestinal carcinoma, and urothelial carcinoma ( 7, 9 - 13 ). (aacrjournals.org)
  • This review describes the use of mRNA-encoded tumor antigens as a form of antigen loaded onto DCs, including our early experience from clinical trials in urological cancers. (nova.edu)
  • The striking observation from two phase I clinical trials, in patients with prostate cancer immunized with prostate-specific antigen mRNA-transfected DCs and patients with renal cancer immunized with autologous tumor RNA-transfected DCs, was that the majority of patients exhibited a vaccine-induced T-cell response. (nova.edu)
  • At the cut-off date, available data demonstrated the long-term persistence of CAR-T cells observed in some patients for more than 100 days, and in one patient for 200 days. (pipelinereview.com)
  • The primary end point was safety and secondary end points included objective response rate, duration of response and T cell persistence. (nature.com)
  • Memory CD8 + T cell responses have the potential to mediate long-lasting protection against cancers. (lifeboat.com)
  • Emerging evidence indicates that Trm cells develop in human solid cancers and play a key role in controlling tumor growth. (lifeboat.com)
  • Therapeutic Candidate or Device Rebecsinib is a novel small molecule inhibitor of ADAR1 splicing that selectively eradicates therapy-resistant cancer stem cells in blood cancers. (ca.gov)
  • Dr. Blumenschein's area of focus is in new drug development, adoptive T-cell therapy and multimodality therapy for the treatment of lung and head and neck cancers. (mdanderson.org)
  • He is leading the Adoptive T-cell Program with the goal of developing this class of therapeutics for the treatment of Lung and Head and Neck Cancers. (mdanderson.org)
  • Jakob JA, Kies MS, Glisson BS, Kupferman ME, Liu DD, Lee JJ, El-Naggar AK, Gonzalez-Angulo AM, Blumenschein GR . A Phase II study of Gefitinib in Patients with Advanced Salivary Gland Cancers. (mdanderson.org)
  • MaxiVAX is a Phase II clinical-stage biotechnology company advancing patient-specific immunomodulatory strategies for the treatment of cancers. (b3cnewswire.com)
  • The company has safely treated over 30 patients in Phase I clinical trial and initiated a 40-patient Phase II clinical trial in head and neck cancers in several clinical sites in Switzerland. (b3cnewswire.com)
  • This approach has proven efficacious in some patients with epithelial cancers, and has been shown to synergize with checkpoint inhibition. (aacr.org)
  • Rosenberg is beginning to develop a library of TCRs that can recognize shared mutations in the hope of utilizing them for TCR T-cell therapy for patients across a variety of tumor types, especially those with common epithelial cancers. (aacr.org)
  • Cancer-testis antigens (CTA) are named after their pattern of expression, as they are found in various types of cancers but only in testicular germ cells of normal adult tissues ( 1 ). (aacrjournals.org)
  • Non-Hodgkin lymphoma is the 2nd most common cancer in HIV-infected patients Неходжкінські лімфоми AIDS-defining cancers in patients infected with HIV are Kaposi sarcoma Lymphoma, Burkitt (or equivalent term) Lymphoma, immunoblastic (or equivalent term) Lymphoma, primary, of central nervous system прочитати більше , and some AIDS patients present with lymphoma. (msdmanuals.com)
  • Due to their proficiency at antigen presentation, DCs are key coordinators in the induction of antitumor immunity. (moffitt.org)
  • Resident memory CD8 + T (Trm) cells stably reside in non-lymphoid tissues and mediate superior innate and adaptive immunity against pathogens. (lifeboat.com)
  • However, the specific contribution of Trm cells to anti-tumor immunity is incompletely understood. (lifeboat.com)
  • 8-10 Long-lasting protective immunity relies on the efficient establishment of long-lived memory CD8 + T cells, which have the potential to eradicate primary and disseminated tumors. (lifeboat.com)
  • Therapeutic Mechanism Destruction of host tumor stem cells by adaptive humoral cellular immunity will eradicate the origin of melanoma which will extend patient survival. (ca.gov)
  • The aim of adoptive T-cell therapy of cancer is to selectively confer immunity against tumor cells. (haematologica.org)
  • The presence of such cancer neoantigen recognizing T cells has been associated with effective antitumor immunity in humans. (patent-art.com)
  • Our basic research focuses on designing a dendritic cell (DC) vaccine targeting glioblastoma multiforme (GBM) cancer stem cells to delay or prevent recurrence following surgery, chemotherapy or radiation. (cedars-sinai.edu)
  • The GBM cancer stem cell vaccine is cellular and consists of patients' autologous dendritic cells infused with tumor lysate from an allogenic glioblastoma cancer stem cell line. (cedars-sinai.edu)
  • ImmunoCellular Therapeutics has decided to use Progenitor Cell Therapy (PCT) to produce its Phase II glioblastoma vaccine, ICT-107. (genengnews.com)
  • Glioblastoma (GB) is the most common and aggressive primary brain tumor in adults and currently incurable. (frontiersin.org)
  • Glioblastoma (GB) is the most frequent malignant primary brain tumor in adults, without any curative treatment options available at present. (frontiersin.org)
  • Despite this aggressive treatment, median survival of glioblastoma patients is only about 15 months, and recurrence remains almost inevitable ( 1 , 2 ). (frontiersin.org)
  • AV-GBM-1, a personalized cancer vaccine, demonstrated an improvement in progression-free survival (PFS) in patients with newly diagnosed glioblastoma, according to data from a phase 2 trial (NCT03400917). (oncnursingnews.com)
  • The improvement in [patients with] glioblastoma who were treated with AV-GBM-1, compared to studies with the standard of care, is a very promising indication that our therapy confers benefit to patients in need," Robert O. Dillman, MD, chief medical officer, of AIVITA Biomedical, Inc, stated in a press release. (oncnursingnews.com)
  • Standard approaches for patients with primary glioblastoma are linked with poor survival outcomes. (oncnursingnews.com)
  • To be eligible for participation, patients had to have a diagnosis of primary glioblastoma, be 70 years of age or younger at the time of tumor resection, have a successful cell culture of cancer cells in serum-free media, have acceptable monocyte collection by leukapheresis, and a Karnofsky performance score (KPS) of 70 or greater following surgical recovery. (oncnursingnews.com)
  • Glioblastoma (GBM) is the most common and fatal primary tumor of the central nervous system (CNS) and current treatments have limited success. (researchportal.be)
  • BACKGROUND: The impact of extent of resection (EOR), residual tumor volume (RTV), and gross-total resection (GTR) in glioblastoma subgroups is currently unknown. (researchportal.be)
  • METHODS: Patients with tumor resection for eloquent glioblastoma between 2010 and 2020 at 4 tertiary centers were recruited from a cohort of 3919 patients. (researchportal.be)
  • Glioblastoma Multiforme (GBM) remains the most common malignant primary brain tumor with a dismal prognosis that rarely exceeds beyond 2 years despite extensive therapy, which consists of maximal safe surgical resection, radiotherapy, and/or chemotherapy. (researchportal.be)
  • In contrast, efforts to improve the current standard of care of newly diagnosed glioblastoma (GB) with, for example, the addition of bevacizumab (BEV), have been largely disappointing and furthermore molecular characterization has not changed therapy except in elderly patients. (surgicalneurologyint.com)
  • Another ACT developed in parallel to CAR T cells is engineering T cells to express TCRs that recognize tumour-associated antigens. (nature.com)
  • We hypothesized that infusion of T cells that have been genetically modified to express affinity-optimized antigen-specific TCRs may help overcome these barriers. (biomedcentral.com)
  • Previous work from the contributing DKTK partner sites has demonstrated the versatility of this approach in T cells, and showed that it is feasible to derive CAR-engineered, established human NK cells as an off-the-shelf cellular therapeutic. (unimedizin-mainz.de)
  • Therapeutic response correlates with the mutational load of the patient tumors, suggesting that neoantigens contribute to tumor rejection. (unimedizin-mainz.de)
  • Therefore, our work highlights the therapeutic potential of vaccination-induced Trm cells to achieve potent protection against skin malignancies. (lifeboat.com)
  • Therapeutic Mechanism Bone marrow transplants are standard of care for AIDS-lymphoma patients providing a cure for the patient's lymphoma. (ca.gov)
  • Therapeutic Candidate or Device The therapeutic product candidate is autologous CD34+ hematopoietic stem/progenitor cells (HSPC) transduced with the G1XCGD lentiviral vector. (ca.gov)
  • Therapeutic Candidate or Device The therapeutic candidate is a patient specific (autologous) induced pluripotent stem cell derived retinal pigment epithelium (AiPSC-RPE) product. (ca.gov)
  • To improve this therapeutic strategy, Rosenberg and colleagues developed a method to identify the exact antigens that the T cells could recognize. (aacr.org)
  • Vaccination against human cancer is a promising therapeutic approach but the optimal antigen or antigens remain undefined. (aacrjournals.org)
  • Furthermore, the ability to isolate and expand cells of sufficient therapeutic quality and quantity in a patient-to-patient model can limit progress. (scienceboard.net)
  • This circumvents the need for any intermediary steps and reduces the time required to produce a cell type for therapeutic use. (scienceboard.net)
  • They are tumor-specific and not expressed by normal cells, which makes them ideal therapeutic targets. (patent-art.com)
  • Neoantigens are mutated peptides present as HLA on the cell surface, and theoretically more attractive therapeutic targets because they are different from the others and seen as non-self by the immune system. (patent-art.com)
  • We have a couple of other modifications that we've been able to make with our therapeutic partners as well, Fate Therapeutics, and that includes high affinity CD-16 that allows us to add a second monoclonal antibody to redirect the cells as well to give it a second kill signal. (urotoday.review)
  • Removing senescent T cells from the physiological cycle to maintain the homeostasis of memory and effector T cells is the way of replacement. (hindawi.com)
  • Accordingly, long-lived memory precursor effector T cells and antigen-specific T cells were increased by PD-1 blockade in intracranial lesions. (bvsalud.org)
  • Dr. Yasuhiro Miyake (Assistant Professor of Okayama University Hospital) with his colleagues have found the presence of anti-60S ribosomal protein L29 (RPL29) antibody in sera, and showed that the anti- recRPL29-peptides polyclonal antibody inhibited the proliferation of human pancreatic cancer Panc-1 cells via the down-regulation of Wnt/β-Catenin signaling pathway in a dose dependent manner. (okayama-u.ac.jp)
  • Anti-RPL29 antibody also showed the suppressive effects on the proliferation of other cancer cells such as lung adenocarcinoma, breast cancer, and hepatocellular carcinoma. (okayama-u.ac.jp)
  • Potential effects of forced CD20 expression on T-cell function were investigated by comparing CD20- and mock-transduced cytomegalovirus (CMV) specific T cells for cytolysis, cytokine release and proliferation. (haematologica.org)
  • Lipid signaling pathways regulate a multitude of cellular behaviors in humans including cell proliferation, death, migration, and many other attributes. (selectbiosciences.com)
  • Nonsynonymous somatic mutations may alter the amino acid coding sequences and create abnormal proteins that become highly expressed and promote cell proliferation. (patent-art.com)
  • Non-Hodgkin lymphomas are a heterogeneous group of disorders involving malignant monoclonal proliferation of lymphoid cells in lymphoreticular sites, including lymph nodes, bone marrow, the spleen, the liver, and the gastrointestinal tract. (msdmanuals.com)
  • Лімфома Ходжкіна Hodgkin lymphoma is a localized or disseminated malignant proliferation of cells of the lymphoreticular system, primarily involving lymph node tissue, spleen, liver, and bone marrow. (msdmanuals.com)
  • These strategies rely on the isolation of T cells, which are either genetically modified to target tumor-specific antigens or are expanded from an endogenous population that recognizes tumor neoantigens. (aacr.org)
  • neoantigens that elicit T-cell responses are identified as immunogenic. (aacr.org)
  • This method allows for improved identification of immunogenic neoantigens beyond those identified by prediction algorithms, and could potentially be applied to all cancer patients - with the caveat that it would be highly individualized and therefore complex, Rosenberg noted. (aacr.org)
  • Tumor-specific antigens (TSAs), also known as neoantigens, are created by the process of genomic codon interchanges, editing, antigen processing and presentation. (patent-art.com)
  • Neoantigens arise from non-synonymous mutations and other genetic alterations in cells. (patent-art.com)
  • Normal cells do not express Neoantigens and therefore, neoantigen-specific immune reactions are not subjected to central and peripheral tolerance. (patent-art.com)
  • Reprogramming is a promising treatment, which redifferentiates T-induced pluripotent stem cells (T-IPSCs) into naïve and cytotoxic T cells or dedifferentiates within their own lineage [ 13 ]. (hindawi.com)
  • Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. (nwbio.com)
  • High-grade glioma (HGG) are the most frequent malignant primary brain tumor, which account for 80% of all gliomas in the United States, and are encountered with an annual incidence of 5.26 per 100,000 population, or 17,000 new cases diagnosed per year. (surgicalneurologyint.com)
  • They're injecting HER2 pulsed dendritic cells (MCC 20915) made from the patient back into their breast tumor before chemotherapy. (moffitt.org)
  • Systemic treatment using chemotherapy is used to treat micrometastatic disease, which is present but not detectable in most patients at diagnosis. (medscape.com)
  • We now demonstrate that EBV-specific cytotoxic T-cell (CTL) lines can readily be generated from individuals with NPC, notwithstanding the patients' prior exposure to chemotherapy/radiation. (nih.gov)
  • In an earlier Phase I study, GBM patients who received ICT-107 in addition to standard treatment with surgery, radiation, and chemotherapy had significantly longer disease-free survival than is typically expected with standard treatment alone. (genengnews.com)
  • Addeo, A., Banna, G. L., Metro, G. & Di Maio, M. Chemotherapy in combination with immune checkpoint inhibitors for the first-line treatment of patients with advanced non-small cell lung cancer: a systematic review and literature-based meta-analysis. (nature.com)
  • PATIENTS AND METHODS: ATALANTE-1 was a two-step open-label study to evaluate the efficacy and safety of OSE2101 compared to standard-of-care (SoC) chemotherapy (CT). (bvsalud.org)
  • Present standard of care for most patients includes surgical resection followed by radio- and chemotherapy. (frontiersin.org)
  • Patients were enrolled to the trial after they recovered from surgery and before they began treatment with concurrent temozolomide chemotherapy and radiation. (oncnursingnews.com)
  • Patients began treatment after they recovered from concurrent treatment with chemotherapy and radiation. (oncnursingnews.com)
  • Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. (survivornet.com)
  • Immuno-oncology approaches have been found to be more effective at long-lasting tumour regression than alternatives such as surgery, radiotherapy, chemotherapy and targeted therapy (1,2). (ddw-online.com)
  • A variety of evidence suggests that spontaneous immune responses to autologous tumor-associated antigens affect the cure of malignant tumors, and that some antibodies in sera could influence cancer cells. (okayama-u.ac.jp)
  • Babatz J, Röllig C, Löbel B, Folprecht G, Haack M, Günther H, Köhne CH, Ehninger G, Schmitz M, Bornhäuser M. Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells. (nwbio.com)
  • This approach allows us to look into mechanisms of immunosuppression by which tumor cells circumvent native and adaptive immune responses. (bmj.com)
  • The analysis of cytokines demonstrated a decrease of serum tumor markers and the reduction of Treg response in the treatment arm, compared to the control arm, and the results suggest a combination of humoral and cell immune responses. (bmj.com)
  • It is now well established that human tumors express unique antigens, however tumor immune evasion mechanisms often prevent effective naturally occurring anti-tumor immune responses. (biomedcentral.com)
  • Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with Myeloma. (cdc.gov)
  • If the tumor is HER2 positive and the patient meets all other eligibility criteria, including having a CNS catheter placed into the tumor resection cavity or into their ventricular system, and meets none of the exclusion criteria, then they can be apheresed, meaning T cells will be collected. (fredhutch.org)
  • These results demonstrate that administration of EBV-specific CTLs to patients with advanced NPC is feasible, appears to be safe, and can be associated with significant antitumor activity. (nih.gov)
  • Focusing on advanced melanoma, we will investigate the antitumor activity of UniCAR NK cells in clinically relevant models. (unimedizin-mainz.de)
  • This GINAKIT2 phase 1 clinical trial, the first to use of genetically engineered NKT cells in humans, will evaluate the anti-tumor activity of GD2 specific CAR and interleukin-15 expressing autologous NKT cells. (texaschildrens.org)
  • The latest addition to oncotherapy is the use of dendritic cell (DC) vaccine therapy. (moffitt.org)
  • A dendritic cell vaccine is a cross between a vaccine and a cell therapy. (moffitt.org)
  • Dendritic cells can be used as a vaccine by preparing together with either peptides or small portions of tumor antigens and they can then be injected into the body. (moffitt.org)
  • Now researchers at Moffitt are working to develop a dendritic cell vaccine targeting HER3, a protein involved in the growth and spread of many different cancer types. (moffitt.org)
  • A DC-based anti-cancer vaccine was evaluated for safety in an academic phase-I/II clinical trial for children, adolescents, and young adults with progressive, recurrent, or primarily metastatic high-risk tumors, mainly sarcomas and neuroblastomas. (muni.cz)
  • The DC vaccine was loaded with self-tumor antigens obtained from patient tumor tissue. (muni.cz)
  • DC vaccine quality was assessed in terms of DC yield, viability, immunophenotype, production of IL-12 and IL-10, and stimulation of allogenic donor T-cells and autologous T-cells in allo-MLR and auto-MLR, respectively. (muni.cz)
  • PCT's cGMP plant in Mountain View, CA, will serve as a second manufacturing site for this dendritic cell-based vaccine. (genengnews.com)
  • Novavax to Use Vivalis' Duck Embryonic Stem Cell Line for Vaccine. (genengnews.com)
  • These findings establish CTAs as potential prognostic markers and as target candidates for vaccine development for patients with urothelial carcinoma. (aacrjournals.org)
  • Results presented during the 2020 SITC Annual Meeting showed that the vaccine resulted in a PFS rate of 69% at 7 months, which favorably compares with the historical rate of 50% at this time point.2 The median PFS was 10.0 months (95% CI, 8.5-11.5) with the vaccine versus 6.9 months (95% CI, 5.8-8.2) in the landmark study that had established the standard of care for this patient population. (oncnursingnews.com)
  • Dendritic cells were generated with autologous tumor antigens from the lysate of the cancer cells to manufacture each patient-specific vaccine. (oncnursingnews.com)
  • In order to generate personalized cancer vaccine, somatic mutations within cancer cells can be identified using whole exome sequencing. (patent-art.com)
  • Oseltamivir resistance in 4 (13.3%) of 30 patients who demic (H1N1) 2009 virus, despite the availability of an ef- were administered oseltamivir highlights the need for ongo- fective vaccine. (cdc.gov)
  • Silencing RPL29 by RNA interference in cancer cells induces the cell cycle arrest at G0/G1 phase and promotes its apoptosis. (okayama-u.ac.jp)
  • Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. (nwbio.com)
  • Tumor-specific T cells are identified, expanded, and infused into the lymphodepleted patient, where they can help mediate tumor regression. (aacr.org)
  • Other successful studies quickly followed, such as those demonstrating sustained complete and partial responses in patients with melanoma and treatment of synovial cell sarcoma with TCR T cells against the NY-ESO-1 antigen. (nature.com)
  • Various biological processes including immunoreaction of infection, tumor prevention, and human aging could cause telomere damage, tumor-related stress responses, and T regulatory (Treg) cells activation, which even trigger T cell senescence showing the distinctive phenotypic and functional alternation [ 9 , 10 ]. (hindawi.com)
  • Moreover, clinically applicable vaccination strategies that efficiently establish Trm cell responses remain largely unexplored and are expected to strongly protect against tumors. (lifeboat.com)
  • Efficacy assessment of the 21 evaluable patients showed a best overall response rate (ORR) of 33% and a disease control rate (DCR) of 67% with one complete response, six partial responses and seven patients with stable disease. (pipelinereview.com)
  • This session was chaired by Padmanee Sharma, MD, PhD , professor in the Department of Genitourinary Medical Oncology at The University of Texas MD Anderson Cancer Center, who opened the plenary by highlighting the incredible breakthrough of checkpoint inhibitors, which are helping many patients to have durable responses. (aacr.org)
  • Two patients achieved complete responses that were ongoing 1.5 years later. (nature.com)
  • Fig. 3: Examples of complete responses mediated by TIL-recognizing tumor antigens. (nature.com)
  • CTAs were first identified by T-cell epitope cloning based on their ability to elicit autologous T-cell responses in a patient with melanoma ( 3 ). (aacrjournals.org)
  • In addition we have compared tumor-specific T cell responses induced by tumor antigen-loaded DC stimulation of TIL to responses induced from PBL. (utmb.edu)
  • Evaluate the influence of anti-CTLA4 on the induction of T cells to non-targeted tumor-associated antigens (antigen-spreading) following adoptive transfer antigen-specific CTL, and the correlation of these responses with clinical outcome. (survivornet.com)
  • Neoantigen-specific T cells are crucial to clinical responses. (patent-art.com)
  • A total of 10 patients diagnosed with advanced NPC were treated with autologous CTLs. (nih.gov)
  • All patients tolerated the CTLs, although one developed increased swelling at the site of pre-existing disease. (nih.gov)
  • T cells, which can efficiently identify and kill infected cells, can also kill cancer cells if they recognize them. (nature.com)
  • This treatment utilizes a patient's own immune system to recognize and attack cancer cells. (aacr.org)
  • 1 T cells are engineered to express CARs through viral vectors, enabling them to recognize specific target antigens. (bdbiosciences.com)
  • Then, immune cells that recognize these cancer proteins are multiplied many times (a process called PLANET™) to create a personalized GEN-011 cell therapy, which is given back to the patient in one or more intravenous (IV) infusions. (uchicagomedicine.org)
  • Provenge is an adoptive cell-transfer therapy in which a patient's antigen-presenting target autologous prostate cancer tissue. (wikipedia.org)
  • However, CAR-T cells can also produce some adverse events after treatment of hematological malignancies, such as cytokine release syndrome (CRS), neurotoxicity, and on-target/off-tumor toxicity, which may cause systemic immune stress inflammation, destruction of the blood-brain barrier, and even normal tissue damage. (hindawi.com)
  • Organoids are generated using tissue-specific stem cells, which are typically undifferentiated epithelial cells. (corning.com)
  • The ability to amplify RNA from microscopic amounts of tumor tissue extends the use of DC vaccination to virtually every cancer patient. (nova.edu)
  • Low-power view of hematoxylin-eosin-stained bone marrow showing hypocellularity, with increased adipose tissue and decreased hematopoietic cells in the marrow space. (medscape.com)
  • In 2006, Rosenberg and colleagues transferred TCR T cells specifically recognizing the melanoma antigen MART-1 in 15 patients, two of whom achieved regression and still showed high levels of engineered cells in circulation one year after the infusion. (nature.com)
  • Taken together, these data show that tumor lysate-pulsed mature DC can consistently restore tumor-specific lytic activity in non-cytotoxic breast cancer TIL. (utmb.edu)
  • 1 , 2 The anti-tumor effect of DLI is mediated by donor T cells recognizing allo-antigens on the malignant cells of the recipient. (haematologica.org)
  • Intracranial metastases are common in nonsmall-cell lung cancer (NSCLC) patients, whose prognosis is very poor. (bvsalud.org)
  • The prognosis for patients with pancreatic cancer is very poor. (okayama-u.ac.jp)
  • Recent studies showed the positive correlation between the concentration of anti-RPL29 antibody in sera of pancreatic cancer patient and its prognosis. (okayama-u.ac.jp)
  • We are grateful for the continued support from both clinicians and regulators that enables us to rapidly advance the clinical evaluation of BNT211 as a novel treatment option for cancer patients with an otherwise very poor prognosis. (pipelinereview.com)
  • Patients diagnosed with GB have a dismal prognosis, and typically succumb to the disease within 3 months if untreated. (frontiersin.org)
  • The results revealed the upregulation of several immunosuppressive markers, including PDL-1, on myeloma cells associated with poor prognosis and trafficking, as well as immunosuppression following T cell infusion. (biomedcentral.com)
  • The World Health Organization (WHO) classification of gliomas is used to define the type and grade of tumor, but the prognosis and response to treatment may vary among tumors even in the same subtype of tumor. (surgicalneurologyint.com)
  • Taking Care of Your Health features cancer-related information, health tips, patient stories and more. (moffitt.org)
  • Dr. Jad Chahoud , a medical oncologist in the Department of Genitourinary Oncology at Moffitt Cancer Center, is conducting a study on dendritic cells for kidney cancer. (moffitt.org)
  • If you'd like to refer a patient to Moffitt Cancer Center, complete our online form or contact a physician liaison for assistance. (moffitt.org)
  • It is also possible to generate organoids from patient cells to investigate the genetic alterations within an individual's cancer cells. (corning.com)
  • Osteosarcoma is the third most common cancer in adolescence-only lymphomas and brain tumors occur more frequently. (medscape.com)
  • Here, we present a cancer vaccination approach utilizing myeloid lineage reprogramming to directly convert cancer cells into tumor reprogrammed-antigen presenting cells (TR-APCs). (lu.se)
  • To address this need, we will link an ImmuNEO module to the DKTK MASTER program that will include exome and transcriptome-sequenced patients on a pan-cancer basis who receive treatment with checkpoint modulators. (unimedizin-mainz.de)
  • RPL29 is one of approximately 80 structural ribosomal proteins, and is highly expressed on the surface of a cancer cell. (okayama-u.ac.jp)
  • Your gift will help support our mission to end cancer and make a difference in the lives of our patients. (mdanderson.org)
  • Their unique approach on cancer immunotherapies addresses a significant unmet medical need for patients with difficult-to-treat tumors. (b3cnewswire.com)
  • Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA. (nwbio.com)
  • Although safety remains a concern, investigators are breaking ground in cell and gene therapy, and many believe that ultimately, a string of cancer cures will follow. (ajmc.com)
  • Essentially, you can kill any cancer cell that has an antigen that is recognized by the immune cell," Hwu said. (ajmc.com)
  • The designation was granted based on the encouraging initial data particularly in patients with testicular cancer which is the most common type of germ cell tumors. (pipelinereview.com)
  • Together with the recently granted PRIME designation for BNT211 in testicular cancer it also reinforces our strategy to combine two of our key technology platforms in hard-to-treat tumor indications," said Prof. Özlem Türeci, M.D., Chief Medical Officer and Co-Founder at BioNTech . (pipelinereview.com)
  • Tumor indications included testicular cancer (n=13), ovarian cancer (n=4), endometrial cancer, fallopian tube cancer, sarcoma, gastric cancer (one patient each) and one patient with a tumor of unknown primary origin. (pipelinereview.com)
  • Caladrius Biosciences is developing an innovative approach to cancer treatment targeting the cells responsible for tumor growth and metastasis, known as cancer stem cells (CSC) or tumor-initiating cells (TIC). (bmj.com)
  • To kick off the session, Sharma introduced Steven Rosenberg, MD, PhD , chief of surgery at the National Cancer Institute, to deliver his talk, "T-cells targeting unique cancer mutations. (aacr.org)
  • Patients with platinum-resistant ovarian cancer and non-small cell lung cancer (adenocarcinoma subtype) were enrolled in the expansion segment of this study. (uci.edu)
  • Patients with platinum-resistant, high-grade serous ovarian cancer are being enrolled in the UPLIFT segment of this study. (uci.edu)
  • This study will evaluate the use of a mobile application in improving the patient-reported health outcome measures (PROMIS) for patients diagnosed with advanced stage ovarian, fallopian tube, and primary peritoneal cancer. (uci.edu)
  • We conducted a single-arm open-label phase 1 trial ( NCT03215810 ) of TILs administered with nivolumab in 20 patients with advanced non-small cell lung cancer following initial progression on nivolumab monotherapy. (nature.com)
  • In exploratory analyses, we found T cells recognizing multiple types of cancer mutations were detected after TIL treatment and were enriched in responding patients. (nature.com)
  • Cell therapy with autologous TILs is generally safe and clinically active and may constitute a new treatment strategy in metastatic lung cancer. (nature.com)
  • These antigens were evaluated for both the degree of expression and prognostic value in cancer of the urothelium. (aacrjournals.org)
  • BACKGROUND: Patients with advanced non-small-cell lung cancer (NSCLC) treated with immune checkpoint blockers (ICBs) ultimately progress either rapidly (primary resistance) or after durable benefit (secondary resistance). (bvsalud.org)
  • BACKGROUND: Several cancer immunotherapies that target the PD-L1/PD-1 pathway show promising clinical activity in patients with hepatocellular carcinoma (HCC). (bvsalud.org)
  • The ACTolog approach targets tumor-specific antigens to fight cancer. (pharmacytimes.com)
  • We believe that attacking multiple cancer targets simultaneously using our tailored approach may lead to promising new treatment options for cancer patients with significant unmet medical need. (pharmacytimes.com)
  • Dendritic cell (DC)-based vaccination for cancer treatment has seen considerable development over recent decades. (researchportal.be)
  • In this study we evaluated the potential of tumor antigen-pulsed fully mature dendritic cell (DC) stimulation in restoring tumor-specific cytotoxicity in anergic TIL populations from advanced breast cancer patients. (utmb.edu)
  • Cancer cells have characteristics of genetic variabilities and accumulate somatic mutations rapidly. (patent-art.com)
  • The genome sequencing of cancer cells has identified heterogeneity and tens to thousands of somatic mutations that vary among individual patients. (patent-art.com)
  • Unlike most T-cell based approaches, this project aims at treating prostate cancer with modified NK cells. (urotoday.review)
  • TiTAN-1 is a first-in-human study of GEN-011, an experimental treatment being evaluated in adult patients with advanced cancer. (uchicagomedicine.org)
  • The rationale of this approach is to bypass mechanisms by which cancer cells dampen the anti-tumor immune response, including down-regulation of MHC Class I molecules. (shu.edu)
  • If the cancer antigens are presented on licensed dendritic cells, logically, the immune system would be appropriately stimulated to attack the cancer. (shu.edu)
  • Transcriptomic profiling of T-cell populations in non-muscle invasive and muscle invasive bladder cancer. (lu.se)
  • CMN-001 is indicated for the treatment of intermediate/poor-risk patients with advanced renal cell carcinoma (RCC) in combination with nivolumab plus ipilimumab as first-line therapy and in combination with lenvatinib plus everolimus as 2nd line therapy post-first-line failure. (moffitt.org)
  • Bleumer I, Tiemessen DM, Oosterwijk-Wakka JC, Völler MC, De Weijer K, Mulders PF, Oosterwijk E. Preliminary analysis of patients with progressive renal cell carcinoma vaccinated with CA9-peptide-pulsed mature dendritic cells. (nwbio.com)
  • An independent data monitoring committee (IDMC) has recommended the continuation of Argos' pivotal phase 3 ADAPT clinical trial of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC) based on results of the committee's second planned interim data analysis . (shu.edu)
  • In the first published gene therapy clinical trial, TILs engineered to express a foreign gene with a retrovirus to mark the infused cells were safely transferred to patients. (nature.com)
  • This was the first clinical use of TCR T cell therapy, and although initial studies had demonstrated the feasibility and safety of introducing engineered T cells in patients, this trial also showed their remarkable efficiency. (nature.com)
  • Moreover, we will review the disadvantages of CAR-T cell therapy and propose several comprehensive recommendations which might guide its development. (hindawi.com)
  • Given successes in the setting of unresectable hepatocellular carcinoma (HCC) and the advantages of neoadjuvant therapy, many trials are demonstrating the safety and feasibility of combination of immune checkpoint inhibitors (ICIs)/tyrosine kinases in patients with resectable HCC. (bvsalud.org)
  • Cell therapy involves cultivating or modifying immune cells outside the body before injecting them into the patient. (ajmc.com)
  • Gene therapy modifies or manipulates cell expression. (ajmc.com)
  • Juliette Hordeaux, PhD, senior director of translational research for the University of Pennsylvania's gene therapy program, is cautious about the FDA's predictions, saying she'd be "thrilled" with 5 cell and/or gene therapy approvals annually. (ajmc.com)
  • Safety has been the main brake around adeno-associated virus vector (AAV) gene therapy," added Hordeaux, whose hospital's program has the institutional memory of both Jesse Gelsinger's tragic death during a 1999 gene therapy trial as well as breakthroughs by Carl June, MD, and others in CAR T-cell therapy. (ajmc.com)
  • Yescarta), a CAR T-cell therapy for adults with large B-cell non-Hodgkin lymphoma. (ajmc.com)
  • Unlike CAR T-cell therapy or TCR therapy, which modifies T cells taken from the blood, TIL therapy utilizes T cells that have infiltrated the tumor stroma, which requires a tumor biopsy. (aacr.org)
  • In 194 consecutive patients treated with this therapy, the overall response rate was 55 percent, with 24 percent of patients achieving a complete response. (aacr.org)
  • The data support the broad value of CD20 as safety switch in adoptive T-cell therapy. (haematologica.org)
  • In this study, we investigated the use of CD20 as safety switch after retroviral transfer to T cells with different cytomegalovirus (CMV) specificities, and conclude that CD20 may be broadly applicable as safeguard in adoptive T-cell therapy. (haematologica.org)
  • Tremendous advances have been made in cell therapy in the past decade. (bdbiosciences.com)
  • A common theme in cell therapy is the need to characterize and understand cell phenotypes and heterogeneity at every step of the process. (bdbiosciences.com)
  • To date, over 10 advanced cell therapy products have been approved -- the majority of which are T-cell-based and strictly autologous. (scienceboard.net)
  • Immatics recently announced patient enrollment into a phase 1 clinical trial of its adoptive cellular therapy (ACT) IMA101, which uses its ACTolog approach. (pharmacytimes.com)
  • The ACTolog technique also creates multiple cell therapy products to target each antigen, which may be more effective than targeting a single antigen, Immatics reported. (pharmacytimes.com)
  • The selection and creation of the ACTolog cell therapy drug is tailored for each patient, making the treatment precise. (pharmacytimes.com)
  • GEN-011 is a T cell therapy made specific to each patient, using the patient's own circulating immune cells. (uchicagomedicine.org)
  • Occassional patients may be candidates for re-irradiation but again there is a paucity of data to commend this therapy and only a minority of selected patients are eligible for this approach. (surgicalneurologyint.com)
  • Cell therapy is poised to play a pivotal role in the development of precision and personalised medicines that will transform healthcare for millions of patients worldwide. (ddw-online.com)
  • This article discusses the challenges facing cell therapy research, and how the latest cell culture technologies are delivering enhanced safety capabilities, improved laboratory performance and, ultimately, optimised cell therapy processes. (ddw-online.com)
  • Because of the huge potential for variability within treatments, an additional challenge in cell therapy is the need for robust manufacturing processes that consistently deliver safe and effective products. (ddw-online.com)
  • Therefore, these patients are likely to oseltamivir therapy. (cdc.gov)
  • Clinicians must stress the need for patient compliance with therapy. (medscape.com)
  • The specific medications administered depend on the choice of therapy and whether it is supportive care only, immunosuppressive therapy, or hematopoietic cell transplantation. (medscape.com)
  • Risk of localized tumors was stable over time after transplantation, but higher with azathioprine maintenance therapy (IRR=1.35, 95%CI 1.03-1.77). (cdc.gov)
  • Загальні відомості про лімфоми Lymphomas are a heterogeneous group of tumors arising in the reticuloendothelial and lymphatic systems. (msdmanuals.com)
  • Two courses of four weekly infusions of rituximab with or without interferon-2a: final results from a randomized phase III study in symptomatic indolent B-cell lymphomas. (cancercentrum.se)
  • The area of research for our group is malignant lymphomas - all possible aspects, aiming for the improvement of the quality of life and survival of these patients. (lu.se)
  • Another example is a T cell that targets only cells that display two separate markers. (wikipedia.org)
  • ICT-107 targets multiple tumor associated antigens. (genengnews.com)
  • The T cells will then be bioengineered into a second-generation CAR T cell that targets HER2-expressing tumor cells. (fredhutch.org)